What does proceeds from sale of future royalties mean?

Cash received from selling the rights to future royalty payments.

How do you interpret proceeds from sale of future royalties?

An increase indicates a strategic decision to monetize assets for immediate cash, while a decrease suggests reliance on other funding sources.

How does proceeds from sale of future royalties compare across companies?

Common in biotech and pharma companies seeking non-dilutive funding to support R&D pipelines.

Ionis Pharmaceuticals IONS Proceeds From Sale Of Future Royalties

Discontinued — last reported Q4 '25

Proceeds From Sale Of Future Royalties at other companies

Revolution Medicines, Inc.RVMD

$61.05M—

Arrowhead ResearchARWR

$0—

Elanco Animal Health Inc.ELAN

$72.5M—

Royalty PharmaRPRX

$3.77M+2,032%

Royalty PharmaRPRX

$915.6M+10.3%

Royalty PharmaRPRX

$25.5M-49.5%

Other financials

Income statement

See full

Revenue$246.1M+87.0%

Gross profit$243.1M+86.8%

Operating income-$117.4M+20.0%

Net income-$92.5M+37.0%

EPS (diluted)-$0.56+39.8%

Balance sheet

See full

Cash & equivalents$173.4M-34.4%

Total debt$691.7M+334%

Total equity$491.4M+3.3%

Total assets$3.4B+22.6%

Cash flow

See full

Operating cash flow-$792.8M-426%

CapEx$21.8M+73.0%

Free cash flow-$814.6M-399%

Valuation

See full

Market cap$12.25B+159%

Enterprise value$12.77B+175%

P/S11.6×+5.0×

Profitability

See full

Gross margin98.4%-0.2pp

Operating margin-33.3%-11.0pp

Net margin-30.9%-10.5pp

FCF margin-77.4%+35.3pp

Returns & leverage

See full

Return on equity-67.6%-20.3pp

Debt / equity1.4×+1.1×

Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept ions:ProceedsFromSaleOfFutureRoyalties.

The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's proceeds from sale of future royalties.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ionis Pharmaceuticals's proceeds from sale of future royalties?: Ionis Pharmaceuticals (IONS) reported proceeds from sale of future royalties of $0 in Q4 2025.
What does proceeds from sale of future royalties mean?: Cash received from selling the rights to future royalty payments.
How do you interpret proceeds from sale of future royalties?: An increase indicates a strategic decision to monetize assets for immediate cash, while a decrease suggests reliance on other funding sources.
How does proceeds from sale of future royalties compare across companies?: Common in biotech and pharma companies seeking non-dilutive funding to support R&D pipelines.